Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
View Older Stories View More Recent Stories
-
Canaccord Genuity Starts Trulieve Cannabis Corp (TRUL:CN) (TCNNF) at Spec. Buy
-
Canaccord Genuity Starts Liberty Health Science Inc. (LHS:CN) (LHSIF) at Spec. Buy
-
LeMaitre Vascular (LMAT) PT Lowered to $32 at Canaccord Genuity
-
Elastic (ESTC) IPO Nearly Doubles on Open
-
CENTAR Announces Signing of Historic Afghan Gold and Copper Mining Agreements
-
Histogenics (HSGX) Prices Public Offering of Common Stock, Warrants
-
Histogenics Corporation Announces Pricing of Public Offering of Common Stock and Warrants
-
Telaria Inc (TLRA) PT Lowered to $6 at Canaccord Genuity
-
Elastic B.V. (ESTC) Prices 7M Share IPO at $36/Sh
-
AtriCure (ATRC) Prices 2.5M Shares Common Offering at $30.75/Sh
-
Elastic Announces Pricing of Initial Public Offering
-
Elastic Announces Pricing of Initial Public Offering
-
AtriCure Announces Pricing of Public Offering of Common Stock
-
Histogenics (HSGX) Announces Proposed Common Share Public Offering
-
Histogenics Corporation Announces Proposed Public Offering of Common Stock and Warrants
-
MediPharm Labs Corp. (TSXV: LABS) (Formerly POCML 4 Inc.) Provides Corporate Update Upon Commencement of Trading on the TSXV
-
MediPharm Labs Corp. (TSXV: LABS) (Formerly POCML 4 Inc.) Provides Corporate Update Upon Commencement of Trading on the TSXV
-
Canaccord Genuity Starts Mercury Computer (MRCY) at Buy
-
ICC Labs Obtains Interim Order for Arrangement With Aurora Cannabis
-
AtriCure (ATRC) Announces Proposed 2.5M Share Common Offering
-
AtriCure Announces Proposed Public Offering of Common Stock
-
CPI Aerostructures (CVU) Court Ruling is Positive says Canaccord
-
Nouveau Monde Graphite Announces Closing of the Final Tranche of Its Private Placement of Units and of Its Private Placement of Flow-Through Shares for an Aggregate of $793,199.60
-
Euro Manganese Inc. Completes IPO for Dual Listing in Canada and Australia, Commences Trading on TSX-V and ASX
-
Euro Manganese Inc. Completes IPO for Dual Listing in Canada and Australia, Commences Trading on TSX-V and ASX
-
TransGlobe Energy Corporation Announces Director/PDMR Shareholding
-
Canaccord Genuity Upgrades Theratechnologies Inc. (TH:CN) (THERF) to Buy
-
Steady Performance Seen Continuing at Superior Plus Corp. (SPB:CN) (SUUIF) - Canaccord Genuity
-
Halo Labs Announces Closing of Business Combination Stock to Commence Trading on October 3rd (NEO:HALO)
-
Tesla shares jump after Musk settles with SEC
-
Behrman Capital Invests in kSARIA Corporation
-
Canaccord Genuity Downgrades Veeva Systems (VEEV) to Hold
-
Canaccord Genuity Downgrades Paycom Software (PAYC) to Hold
-
Americas Silver Corporation and Pershing Gold Corporation Announce Business Combination
-
Americas Silver Corporation and Pershing Gold Corporation Announce Business Combination
-
Belvedere Announces Second Tranche Closing of Non-Brokered Private Placement Undertaken in Connection With Proposed Change of Business Transaction
-
UPDATE: BlackBerry Limited (BB) PT Raised to $11 at Canaccord Genuity
-
Wayfair (W) PT Raised to $165 at Canaccord Genuity
-
Teladoc (TDOC) PT Raised to $94 at Canaccord Genuity
-
CalAmp Corp. (CAMP) PT Raised to $31 at Canaccord Genuity
-
CalAmp Corp. (CAMP) PT Raised to $31 at Canaccord Genuity
-
IQE plc: Total voting rights
-
Ericsson (ERIC) PT Raised to $9 at Canaccord Genuity
-
Final Results
-
Histogenics (HSGX) to Meet With FDA to Discuss NeoCart Phase 3 Clinical Trial Data, Potential Regulatory Pathway
-
Histogenics to Meet With FDA to Discuss NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway
-
UPDATE: Aldeyra Therapeutics (ALDX) PT Raised to 'Street High' $35 at Canaccord Genuity
-
Absolute Announces Approval of Normal Course Issuer Bid
-
Catasys (CATS) PT Raised to $15 at Canaccord Genuity
-
Y-mAbs Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

